| Identification | Back Directory | [Name]
3H-Cyclopenta[c]quinoline, 3a,4,5,9b-tetrahydro-8-nitro-4-phenyl- | [CAS]
353495-21-3 | [Synonyms]
BAP1-IN-1
3H-Cyclopenta[c]quinoline, 3a,4,5,9b-tetrahydro-8-nitro-4-phenyl- | [Molecular Formula]
C18H16N2O2 | [MOL File]
353495-21-3.mol | [Molecular Weight]
292.33 |
| Chemical Properties | Back Directory | [Boiling point ]
454.3±45.0 °C(Predicted) | [density ]
1.239±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
0.26±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
BAP1-IN-1 (Compound 8) is a BRCA1 associated protein 1 (BAP1) catalytic activity inhibitor with an IC50 of 0.1-1 μM[1]. | [in vivo]
BAP1-IN-1 (Compound 8) (50 mg/kg/d; i.p.; 4 weeks) delays the progression of ASXL1-mutant leukemia and improves survival in mice[1]. | Animal Model: | NSGS mice, K562 (ASXL1-WT/Y591*) xenograft model and patient-derived tumor cells (ASXL1-WT/Q588*) model[1] | | Dosage: | 50 mg/kg/d | | Administration: | Intraperitoneal injection, drug treatments were started at day 28 after transplantation | | Result: | Significantly delayed progression of disease in both models. |
| [References]
[1] Wang L, et al. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia. Nat Cancer. 2021 May;2(5):515-526. DOI:10.1038/s43018-021-00199-4 |
|
| Company Name: |
DebyeTec.com Inc.
|
| Tel: |
18086626237 18086626237 |
| Website: |
www.chemicalbook.com/showsupplierproductslist16955/0.htm |
|